Drugs / AG-73305
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05301751 | May 2022 → Sep 2023 | diabetic macular edema | Allgenesis Biotherapeutics Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2023-11-09 | Allgenesis Biotherapeutics Inc. | Results 鼓舞人心的AG-73305臨床 2a試驗數據顯示了初步安全性和有效性 allgenesis.com ↗
新源生技首次公佈人體2a期臨床試驗令人振奮的初步數據，試驗中評估了AG-73305對糖尿病黃斑部水腫(DME)患者的安全性、耐受性和有效性。 |
| 2023-11-08 | Allgenesis Biotherapeutics Inc. | Results Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology allgenesis.com ↗
Data combining all 4 cohorts showed mean improvement in Best Corrected Visual Accuity (BCVA) of +6.4 ETDRS letters with mean Central Subfield Thickness (CST) improvements of -100 microns at 4 weeks post-injection. |
| 2023-09-30 | Allgenesis Biotherapeutics Inc. | Results Allgenesis to Present Initial Data from Phase 2a Study of AG-73305, a Novel Bispecific Anti-VEGF and Anti-Integrin Fc-Fusion Protein for the Treatment of DME at AAO 2023 allgenesis.com ↗
AG-73305 was found to be safe, with no dose limiting toxicities or AEs leading to withdrawal from the study. |
| 2023-05-29 | Allgenesis Biotherapeutics Inc. | Results Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema allgenesis.com ↗
Preliminary data from the 0.5 mg (n=3) and 1 mg (n=3) cohorts demonstrated that AG-73305 was safe and tolerable after a single intravitreal injection. |
| 2023-05-25 | AffaMed Therapeutics Limited | Results AffaMed Therapeutics Announces Partner Allgenesis Reports Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema affamed.com ↗
Preliminary data from the 0.5 mg (n=3) and 1 mg (n=3) cohorts demonstrated that AG-73305 was safe and tolerable after a single intravitreal injection. |
| 2022-03-31 | Allgenesis Biotherapeutics Inc. | Regulatory Allgenesis Announces FDA Clearance of the IND for AG-73305 for the Treatment of Diabetic Macular Edema allgenesis.com ↗ |
| 2020-02-05 | Allgenesis Biotherapeutics Inc. | Regulatory Allgenesis Receives Notice of Grant of Japanese Patent for anti-VEGF/Disintegrin Fusion Protein allgenesis.com ↗ |
All press releases naming this drug 13 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AG-73305 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05301751 ↗ |
| Route | Intravitreal | “AG-73305 administered by intravitreal injection” NCT05301751 ↗ |